-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Lyell Reports Ronde-Cel Shows High Durable Complete Responses In LBCL With 93% ORR And 76% CR In 3L+ Setting At ASH 2025

Benzinga·12/08/2025 08:21:56
Listen to the news
  • 93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting
  • 83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L setting
  • Manageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone prophylaxis
  • Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, Associate Professor at the David Geffen School of Medicine, University of California, Los Angeles, at 8:30 AM ET on Monday, December 8th